FORT LAUDERDALE, Fla., Oct. 06, 2016 -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced that Scientia Clinical Research, Australia’s newest and most advanced early phase clinical trial facility at the University of New South Wales in Sydney, Australia has selected OmniComm’s TrialOne clinic automation and eSource application. Scientia Clinical Research is the first purpose built early phase clinical trials center in Sydney, Australia. In addition to first-in-human and first-in-patient studies, the facility will also support later phase trials across a broad range of disciplines. TrialOne will standardize processes, improve business intelligence, ensure compliance, and achieve overall business transformation within its early phase research.
“Scientia Clinical Research believes TrialOne will deliver a competitive advantage in the early phase clinical trial space in Australia,” says Lisa Nelson, CEO at Scientia Clinical Research.
TrialOne is a browser-based bedside data collection technology specifically designed to automate the workflows and processes within early phase research clinics. TrialOne enables the automation of clinic data collection; standardizes recruiting; facilitates the collection of study data and sample tracking; reduces discrepancies inherent in paper-based applications; and ensures compliance.
TrialOne is the market leading eSource system for early phase research clinics addressing the following needs of this organization:
- Manage and optimize patient screening and recruitment
- Provide secure and fully validated eSource
- Implement protocol compliant workflows and data capture from subject bedside
- Deliver automated data capture from medical monitoring equipment and devices
- Streamline staff training and support records
- Provide integration with laboratory information management systems (LIMS) for lab orders and lab results processing
“We are extremely proud that Scientia Clinical Research selected TrialOne early phase clinic automation solution for their state of the art, purpose built clinical trial center. Scientia is OmniComm’s first customer in Australia and New Zealand. This represents a decisive step for OmniComm in its penetration of the early phase and clinical trials market in Australia. Having Scientia as a high profile, top level customer will aid OmniComm in its regional expansion, not only with TrialOne but with all our products,” says Wolf Ondracek, managing director and SVP for the APAC region at OmniComm. “We are extremely pleased to be partnering and working with such a world-class organization as Scientia Clinical Research.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,800 clinical trials. For more information, visit www.omnicomm.com.
Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Dennis Constantinou OmniComm Systems, Inc. +1.954.473.1254 [email protected]


TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
OpenAI Explores Massive Funding Round at $750 Billion Valuation
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 



